Phase II Study of Weekly Paclitaxel for Docetaxel-Resistant Metastatic Breast Cancer in Japan

Department of Surgical Oncology, Osaka University Graduate School of Medicine, 2-2 E10 Yamadaoka, Suita, Osaka, 565-0871, Japan.
The Breast Journal (Impact Factor: 1.43). 11/2004; 10(6):509-13. DOI: 10.1111/j.1075-122X.2004.21555.x
Source: PubMed

ABSTRACT The purpose of the study was to evaluate the efficacy of weekly paclitaxel (PTX) against metastatic breast cancer (MBC) that was resistant to docetaxel (DTX) given every 3 weeks. A multicenter phase II study was performed. Women with MBC resistant to DTX were eligible for enrollment. DTX resistance was defined as no tumor response to DTX and stable disease, partial response, or complete response to DTX preceding disease progression. PTX 80 mg/m(2) was administered over 1 hour once a week for 3 weeks per 4-week cycle. Among 47 enrolled patients, 46 patients were assessable for response and toxicity. The overall objective response rate (complete responses [CRs] and partial responses [PRs]) was 17.4% and overall clinical benefit rate (CRs, PRs, and stable disease >or=24 weeks) was 26.1%. The median time to progression was 11 weeks. There were a few severe hematologic toxicities related to the therapy, with grade 4 neutropenia (4.3%) and thrombocytopenia (2.2%). Grade 3 anaphylaxis and grade 3 neuropathy were observed in one patient (2.2%) each. The median delivered dose intensity was 77.6 mg/m(2)/week, 97.1% of the planned dose intensity. Weekly PTX has activity in patients with MBC resistant to DTX every 3 weeks.

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer. Patients were treated with paclitaxel at the dose of 135 mg/m(2) followed by carboplatin AUC 3 on day 1 every 2 weeks in cycles of 28 days. Thirty-eight patients with castration-resistant prostate cancer were enrolled, and all of them had received frontline chemotherapy with docetaxel and prednisone, while 24 (63.2 %) had received 2 or more prior chemotherapy regimens. In an intention-to-treatment analysis, a clinical and/or biochemical response (>50 % decline) was observed in 10 patients (26.3 %; 95 % CI, 12.3-40.3 %), stable disease in 13 (34.2 %) and progressive disease in 15 (39.5 %). The median duration of response was 6.1 months (range, 1.0-9.8), the median time to tumor progression (TTP) 3.6 months (95 % CI, 2.1-5.2) and the median overall survival 9.9 months (95 % CI, 6.2-13.6). The probability for 1-year survival was 43 %. Grade 3 and 4 neutropenia was observed in three (7.9 %) and nine (23.7 %) patients, respectively. The biweekly administration of paclitaxel/carboplatin regimen in patients with castration-resistant prostate cancer is an active and well-tolerated regimen which merits to be further evaluated in the context of salvage treatment.
    Cancer Chemotherapy and Pharmacology 06/2012; 70(1):161-8. DOI:10.1007/s00280-012-1896-9 · 2.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reaction mechanisms of alkaline hydrolysis of N-(2-methoxyphenyl) benzamide have been investigated using density functional theory (DFT). The whole reaction could be regarded as a successive process that consisted of two main stages: generation of the tetrahedral intermediate (M1) and the transformation from M1 to the final products. Three reaction channels were proposed for the second stage. Channel 1 is an intramolecular proton migration process. In channel 2 and channel 3, which could be regarded as an intermolecular proton migration process, the water molecule participates in the reaction and becomes a medium of proton transferring. We found that the rate-determining activation energy required for channel 2 and 3 is lower than channel 1, which indicates that the water not only acts as the solvent, but also plays an important role in the reaction. And this reaction could occur easily at room temperature, which is in good agreement with the experiments.
    Computational and Theoretical Chemistry 02/2011; 963(2):268-272. DOI:10.1016/j.comptc.2010.10.036 · 1.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this work was to assess and quantify polyphenols and hydroxycinnamic acids in different parts of the heads of 6 globe artichoke cultivars by HPLC–DAD–MS/MS. Globe artichoke (Cynara cardunculus var. scolymus) has been used in folk medicine since Roman times, possibly because of high hydroxycinnamic acid and flavone levels. However, to our knowledge, little is known about how these compounds are distributed in different parts of the artichoke head (outer bracts, inner bracts and receptacle). The phenolic profile was significantly different between cultivars and in different parts of the head, suggesting that individual compounds are accumulated preferentially in specific head parts and cultivars. In particular, the phenolic profile of the outer bracts exhibits very low (443mgkg−1 dry matter) or zero hydroxycinnamic acid content, and these compounds are present mainly in the receptacle (the edible part; mean value, 1473mgkg−1 dry matter). This study presents data that indicate the different levels of phenolics in different parts of artichoke, and shows the potential of various artichoke parts as a source of different levels of dietary phenolics.
    Journal of Food Composition and Analysis 03/2011; 24(2):148-153. DOI:10.1016/j.jfca.2010.04.010 · 2.26 Impact Factor